Industry News (Therapy)

Results of LGD1069 Used To Treat Kaposi's Sarcoma Presented

Published in Cancer Weekly, October 16th, 1995

Ligand Pharmaceuticals Inc., San Francisco, California, announced interim results of controlled Phase I/IIb human clinical trials indicating that Targretin Topical (LGD1069) induced a partial or complete response in one or more treated lesions in 52 percent of 23 patients with AIDS-related Kaposi's sarcoma (KS) evaluated to date by AIDS Clinical Trial Group criteria.

Data were presented on the first 23 of 51 patients enrolled in the multicenter trial as of September 15, 1995. These patients had received treatment for at least two months with Targretin Topical (LGD1069), a compound discovered by Ligand scientists which selectively activates a subclass of retinoid...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1995-10-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry